Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What You Need To Know Ahead of Merck's Earnings Release

Valued at a market cap of $204.3 billion, Merck & Co., Inc. (MRK) is a global healthcare company with a diverse portfolio spanning pharmaceuticals and animal health. Best known for its blockbuster cancer drug Keytruda, Merck has driven consistent growth through innovative therapies, strategic acquisitions, and global partnerships. The company is slated to announce its fiscal Q2 2025 earnings results before the market opens on Tuesday, Jul. 29. 

Ahead of the event, analysts expect the Rahway, New Jersey-based company to report an adjusted EPS of $2.04, down 10.5% from $2.28 in the year-ago quarter. However, the company has surpassed Wall Street's bottom-line estimates in...

Fundamentals

See More
  • Market Capitalization, $K 204,322,592
  • Shares Outstanding, K 2,511,031
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 20,398 M
  • EBITDA $ 24,897 M
  • 60-Month Beta 0.39
  • Price/Sales 3.17
  • Price/Cash Flow 8.55
  • Price/Book 4.22

Options Overview Details

View History
  • Implied Volatility 35.27% ( -0.83%)
  • Historical Volatility 22.78%
  • IV Percentile 85%
  • IV Rank 49.78%
  • IV High 53.48% on 04/10/25
  • IV Low 17.23% on 09/23/24
  • Put/Call Vol Ratio 0.47
  • Today's Volume 59,766
  • Volume Avg (30-Day) 50,616
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 725,800
  • Open Int (30-Day) 747,276

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 2.04
  • Number of Estimates 7
  • High Estimate 2.14
  • Low Estimate 1.94
  • Prior Year 2.28
  • Growth Rate Est. (year over year) -10.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.10 +8.57%
on 06/18/25
84.48 -0.91%
on 07/09/25
+4.38 (+5.52%)
since 06/09/25
3-Month
73.31 +14.19%
on 05/15/25
85.83 -2.47%
on 04/30/25
+1.80 (+2.20%)
since 04/09/25
52-Week
73.31 +14.19%
on 05/15/25
129.93 -35.57%
on 07/12/24
-42.33 (-33.58%)
since 07/09/24

Most Recent Stories

More News
Stocks Settle Higher on Tech Stock Strength and Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +0.61%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.72%. September E-mini...

MSTR : 415.41 (+4.65%)
GOOGL : 176.62 (+1.30%)
AAPL : 211.14 (+0.54%)
BE : 28.71 (+18.15%)
DHI : 138.41 (+5.36%)
MRK : 83.71 (+2.88%)
VRNA : 104.77 (+20.62%)
$IUXX : 22,864.91 (+0.72%)
COIN : 373.85 (+5.36%)
UNH : 302.91 (-1.56%)
FICO : 1,591.73 (-6.54%)
ZNU25 : 111-095 (+0.03%)
Stocks Climb on Strength in the Magnificent Seven Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.28%. September E-mini S&P futures (ESU25...

GOOGL : 176.62 (+1.30%)
BE : 28.71 (+18.15%)
MRK : 83.71 (+2.88%)
VRNA : 104.77 (+20.62%)
WYNN : 110.08 (-0.34%)
$IUXX : 22,864.91 (+0.72%)
UNH : 302.91 (-1.56%)
ZNU25 : 111-095 (+0.03%)
MSFT : 503.51 (+1.39%)
ESU25 : 6,292.50 (-0.23%)
SBUX : 95.25 (+0.33%)
$DOWI : 44,458.30 (+0.49%)
What You Need To Know Ahead of Merck's Earnings Release

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

XLV : 135.49 (+0.39%)
$SPX : 6,263.26 (+0.61%)
MRK : 83.71 (+2.88%)
Merck Faces Multiple Challenges: Will It Steer Through Successfully?

Merck MRK is expected to face several hurdles over the next few years that could affect its long-term growth trajectory, starting with the anticipated loss of exclusivity of its blockbuster PD-L1 inhibitor,...

JNJ : 156.28 (+0.31%)
MRK : 83.71 (+2.88%)
LLY : 786.92 (+1.19%)
PFE : 25.56 (-0.23%)
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents close...

AZN : 70.82 (+1.14%)
MRK : 83.71 (+2.88%)
GSK : 39.04 (+1.46%)
SNY : 48.83 (+1.35%)
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?

Bristol Myers’ BMY growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others.Among these, immuno-oncology drug Opdivo...

MRK : 83.71 (+2.88%)
RHHBY : 40.8700 (+1.95%)
BMY : 47.66 (+1.32%)
Stocks See Support as Investors Await Tariff News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.66%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.83%. September E-mini S&P futures (ESU25...

BE : 28.71 (+18.15%)
MRK : 83.71 (+2.88%)
VRNA : 104.77 (+20.62%)
WYNN : 110.08 (-0.34%)
$IUXX : 22,864.91 (+0.72%)
ZNU25 : 111-095 (+0.03%)
MSFT : 503.51 (+1.39%)
ESU25 : 6,292.50 (-0.23%)
SBUX : 95.25 (+0.33%)
$DOWI : 44,458.30 (+0.49%)
SCCO : 99.92 (-2.99%)
DOCS : 63.26 (+2.91%)
Merck spends $10 billion for Verona, gaining access to its COPD medication

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal

$SPX : 6,263.26 (+0.61%)
MRK : 83.71 (+2.88%)
$DOWI : 44,458.30 (+0.49%)
$IUXX : 22,864.91 (+0.72%)
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6...

AZN : 70.82 (+1.14%)
MRK : 83.71 (+2.88%)
PFE : 25.56 (-0.23%)
BMY : 47.66 (+1.32%)
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The stock has also outperformed the sector and the S&P 500 index in this time frame.Gilead...

MRK : 83.71 (+2.88%)
GILD : 113.24 (+1.96%)
GSK : 39.04 (+1.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 87.42
2nd Resistance Point 85.95
1st Resistance Point 84.83
Last Price 83.71
1st Support Level 82.24
2nd Support Level 80.77
3rd Support Level 79.65

See More

52-Week High 129.93
Fibonacci 61.8% 108.30
Fibonacci 50% 101.62
Fibonacci 38.2% 94.94
Last Price 83.71
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar